To identify patients with a high risk of recurrence, who benefit from adjuvant chemotherapy, and to avoid overtreating patients with a low risk of recurrence, several prospective and retrospective studies were conducted in hormone receptor (HR) positive, and normal expression of human epidermal growth factor receptor-2 (HER2) BC. Here, ERBB2 is linked to breast cancer.